Pregled bibliografske jedinice broj: 1137086
Genetics of prostate carcinoma
Genetics of prostate carcinoma // Acta Medica Academica, 50 (2021), 1; 71-87 doi:10.5644/ama2006-124.327 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1137086 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Genetics of prostate carcinoma
Autori
Krušlin, Božo ; Škara, Lucija ; Vodopić, Tonći ; Vrhovec, Borna ; Murgić, Jure ; Štimac, Goran ; Fröbe, Ana ; Lež, Cvjetko ; Ulamec, Monika ; Gall Trošelj, Koraljka
Izvornik
Acta Medica Academica (1840-1848) 50
(2021), 1;
71-87
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
prostate cancer ; genetic changes ; molecular subtypes ; treatment
Sažetak
The aim of this review is to provide a brief overview of some current approaches regarding diagnostics, pathologic features, treatment, and genetics of prostate carcinoma (PCa). Prostate carcinoma is the most common visceral tumor and the second most common cancer-related cause of death in males. Clinical outcomes for patients with localized prostate cancer are excellent, but despite advances in prostate cancer treatments, castrate-resistant prostate cancer and metastatic prostate cancer patients have a poor prognosis. Advanced large-scale genomic studies revealed a large number of genetic alterations in prostate cancer. The meaning of these alterations needs to be validated in the specific prostate cancer molecular subtype context. Along these lines, there is a critical need for establishing genetically engineered mouse models, which would include speckle type BTB/POZ protein and isocitrate Dehydrogenase (NADP (+)) 1 mutant, as well as androgen receptor neuroendocrine subtypes of prostate cancer. Another urgent need is developing highly metastatic prostate cancer models, as only up to 17% of available models dis- play bone metastases and exhibit a less typical neuroendocrine prostate cancer or sarcomatoid carcinoma. Moreover, androgen deprivation and relapse should be mimicked in the genetically engineered mouse models, as androgen independence may yield a better model for metastatic castrate-resistant prostate cancer. The development of such refined animal models should be guid- ed by comparative genomics of primary versus corresponding metastatic tumors. Such an approach will have the potential to illuminate the key genetic events associated with specific molecular prostate cancer subsets and indicate directions for effective therapy.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
HRZZ-IP-2016-06-4404 - NRF2 na raskrižju epigenetičkog modeliranja, metabolizma i proliferacije stanice raka (CrossEMPATICNRF2) (Gall-Trošelj, Koraljka, HRZZ - 2016-06) ( CroRIS)
Ustanove:
Stomatološki fakultet, Zagreb,
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Opća bolnica Varaždin,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
Lucija Škara
(autor)
Jure Murgić
(autor)
Monika Ulamec
(autor)
Cvjetko Lež
(autor)
Koraljka Gall Trošelj
(autor)
Goran Štimac
(autor)
Božo Krušlin
(autor)
Ana Fröbe
(autor)
Borna Vrhovec
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- CAB Abstracts
- EBSCOhost
- IndexScholar
- DOAJ
- CrossRef
- InfoBase Index